Resistance Trends of Antiretroviral Agents in People with Human Immunodeficiency Virus in Korea, 2012 - 2020
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: Domestic data on antiretroviral drug (ARV) resistance are limited, while alterations in ARV resistance are expected as the incidence of human immunodeficiency virus (HIV) infection increases. We evaluated the ten-year change in ARV resistance in people with HIV (PWH) in Korea. Materials and Methods: Adults aged ≥19 years and diagnosed with HIV infection between January 2010 and December 2020 at a 750-bed municipal hospital were retrospectively reviewed. Data on clinical characteristics and resistance mutation test results were collected. The study population was divided into three-year intervals according to diagnosed year and their clinical characteristics were compared. Results: A total of 248 PWH were analyzed, and ARV resistance was detected in 30 of them (12.1%). Resistance was detected most frequently in PWH aged ≤29 years (16, 6.5%), and the median percentage of resistance detection per year was 14.3% (interquartile range, 12.7 - 16.1). The trend of the overall prevalence of ARV resistance mutations slightly decreased and then increased over time (15.3% in 2012 - 2014, 9.6% in 2015 - 2017, and 12.9% in 2018 - 2020). The prevalence of the non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance markedly decreased over time (15.3% in 2012 - 2014, 8.7% in 2015 - 2017, and 2.4% in 2018-2020), while that of protease inhibitor (PI) and integrase strand transfer inhibitor (INSTI) increased from 0 until 2018 to 3.5% and 8.2% in 2018 - 2020, respectively. Conclusion: The trend of NNRTI resistance has decreased over time, and resistance to PIs and INSTIs increased from 2018. Therefore, continuous monitoring of ARV resistance pattern is necessary.
Abstract
Background: Domestic data on antiretroviral drug (ARV) resistance are limited, while alterations in ARV resistance are expected as the incidence of human immunodeficiency virus (HIV) infection increases. We evaluated the ten-year change in ARV resistance in people with HIV (PWH) in Korea. Materials and Methods: Adults aged ≥19 years and diagnosed with HIV infection between January 2010 and December 2020 at a 750-bed municipal hospital were retrospectively reviewed. Data on clinical characteristics and resistance mutation test results were collected. The study population was divided into three-year intervals according to diagnosed year and their clinical characteristics were compared. Results: A total of 248 PWH were analyzed, and ARV resistance was detected in 30 of them (12.1%). Resistance was detected most frequently in PWH aged ≤29 years (16, 6.5%), and the median percentage of resistance detection per year was 14.3% (interquartile range, 12.7 - 16.1). The trend of the overall prevalence of ARV resistance mutations slightly decreased and then increased over time (15.3% in 2012 - 2014, 9.6% in 2015 - 2017, and 12.9% in 2018 - 2020). The prevalence of the non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance markedly decreased over time (15.3% in 2012 - 2014, 8.7% in 2015 - 2017, and 2.4% in 2018-2020), while that of protease inhibitor (PI) and integrase strand transfer inhibitor (INSTI) increased from 0 until 2018 to 3.5% and 8.2% in 2018 - 2020, respectively. Conclusion: The trend of NNRTI resistance has decreased over time, and resistance to PIs and INSTIs increased from 2018. Therefore, continuous monitoring of ARV resistance pattern is necessary.
참고문헌 (24)
- "Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV"[URL]
- "EACS guidelines 2021"[URL]
- Saag MS, "Antiretroviral drugs for treatment and prevention of HIV infection in adults : 2020 recommendations of the International Antiviral Society-USA panel", JAMA, 324, pp.1651~1669 (2020)
- The Korean Society for AIDS, "Summary of 2021 Clinical Guidelines for the Diagnosis and Treatment of HIV", AIDS in HIV-infected Koreans, 2021, pp.53(3), 592~616[DOI]
- 대한에이즈학회, "Summary of Guidelines for the Use of Pre-Exposure Prophylaxis for HIV in Korea", Infection and Chemotherapy, 49(3), pp.243~246 (2017), 대한감염학회
- Lebelonyane R, "Rapid antiretroviral therapy initiation in the Botswana Combination Prevention Project : a quasi-experimental before and after study", Lancet HIV, 7, pp.e545~53 (2020)
- Clavel F, "HIV drug resistance", N Engl J Med, 350, pp.1023~1035 (2004)
- van de Vijver DA, "Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa : a comparison of mathematical models", AIDS, 27, pp.2943~2951 (2013)
- Cambiano V, "Predicted levels of HIV drug resistance : potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation", AIDS, 28(Suppl 1), pp.S15~23 (2014)
- "HIV drug resistance report 2021"[URL]
- "HIV drug resistance strategy" (2021)[URL]
- 김서린, "치료력이 없는 HIV 감염환자에서 약제내성 빈도", 대한내과학회지, 73(3), pp.243~250 (2007), 대한내과학회
- "Major HIV-1 drug resistance mutations" (2022)[URL]
- Jung EJ, "Short communication : trends in transmitted drug resistance in treatment-naive HIV patients in Korea", AIDS Res Hum Retroviruses, 36, pp.905~909 (2020)
- Delviks-Frankenberry KA, "The"Connection"between HIV drug resistance and RNase H", Viruses, 2, pp.1476~1503 (2010)
- Tang MW, "HIV-1 antiretroviral resistance : scientific principles and clinical applications", Drugs, 72, pp.e1~25 (2012)
- Wensing AM, "2019 update of the drug resistance mutations in HIV-1", Top Antivir Med, 27, pp.111~121 (2019)
- Wirden M, "Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients", Antimicrob Agents Chemother, 50, pp.2553~2556 (2006)
- Violin M, "Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy", AIDS, 18, pp.227~235 (2004)
- Vingerhoets J, "Resistance profile of etravirine : combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies", AIDS, 24, pp.503~514 (2010)
- Gallant JE, "Antiretroviral drug resistance and resistance testing", Top HIV Med, 13, pp.138~142 (2005)
- Anstett K, "Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity", J Antimicrob Chemother, 71, pp.2083~2088 (2016)
- Lange JM, "The discovery and development of antiretroviral agents", Antivir Ther, 19(Suppl 3), pp.5~14 (2014)
- "2020 HIV/AIDS report status"[URL]